According to the current analysis of Reports and Data, the global Preimplantation genetic testing market was valued at USD 347.7 million in 2018 and is expected to reach USD 762.6 million by the year 2026, at a CAGR of 10.1%. Preimplantation Genetic testing identifies genetic defects in embryos, which are developed through Vitro Fertilization (IVF) before pregnancy. Preimplantation genetic diagnosis (PGD) is made when one or both the hereditary parents have a known hereditary disorder, and testing is performed on the embryo to determine whether it carries the same hereditary disorder. It is used is growing due to; increasing number of cases related to the predominance of genetic, hereditary and chromosomal diseases, rising knowledge amongst the population about the avoidance of genetic disorders.
A growing number of people suffering from genetic diseases are expected to increase demand for preimplantation genetic testing procedures to have a healthy child. Due to high pregnancy chances with the preimplantation genetic testing procedure as compared to other fertility treatments, the demand for PGI testing is expected to witness high demand among people seeking IVF treatments.
Market Overview:
The pharma and healthcare industry is at a crossroads. Patients are benefiting from the promise of cell and gene therapies; uncommon diseases that were previously thought to be incurable are on the verge of finding true treatments. Artificial intelligence (AI) and machine-learning technologies are creating hopes that therapy discovery and development would be more innovative, as well as faster and cheaper. Manufacturing, the supply chain, and the entire healthcare ecosystem all have the potential to benefit from data-driven initiatives. Consumer attitudes and behaviours are shifting in a variety of ways, from growing use of technology and willingness to share data to an interest in using tools to make prescription and treatment decisions. Such factors will drive pharma and healthcare market growth in the coming years.
Some key highlights of the report:
- Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
- Preimplantation Genetic Screening (PGS) seems to be a reasonable intervention to enhance the efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in the near future
- Advancements in the detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
- The market chromosomal abnormalities segment is expected to reach USD 271.0 million by the year 2026, growing at a CAGR of 6.8% during the forecast period
- Enlarging utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is anticipated to fuel the growth of X-linked diseases segment
- Increasing use Of PGT in embryo HLA typing for stem cell therapy is expected to boost segment growth. This further proceeds to the advantages of PGS testing for the identification of HLA compatible embryos during stem cell therapy
- North America holds the largest revenue share of 32.0% in 2018 due to an increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures.
- Asia Pacificmarket is observed to showcase the fastest growing CAGR due to the rise in medical tourism and rising development of IVF and PGD clinics in Asian countries.
Key Players covered in this report are
PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
Test Type (Revenue, USD Million; 2016–2026)
- Preimplantation Genetic Diagnosis (PGD)
- Preimplantation Genetic Screening (PGS)
Type (Revenue, USD Million; 2016–2026)
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Fresh Embryo (Own Eggs)
- Frozen Embryo (Own Eggs)
- Fresh Embryo (Donor Eggs)
- Frozen Embryo (Donor Eggs)
- Aneuploidy Screening
- HLA Typing
- Other PGT Types
Application (Revenue, USD Million; 2016–2026)
- Embryo HLA Typing for Stem Cell Therapy
- IVF Prognosis
- Late Onset Genetic Disorders
- Inherited Genetic Disease
- Others
End Use (Revenue, USD Million; 2016–2026)
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs, and Service Providers
- Research Laboratories & Academic Institutes
Key Regional Markets Studied in the Report:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- The Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2244
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
